ACP medicine, 3rd Edition

Gastroenterology

Gallstones and Biliary Tract Disease

Kimberly M. Persley MD1

Rajeev Jain MD, FACP2

1Assistant Clinical Professor of Medicine, University of Texas Southwestern Medical Center at Dallas, Staff Physician, Presbyterian Hospital of Dallas

2Assistant Clinical Professor of Medicine, University of Texas Southwestern Medical Center at Dallas, Chief of Gastroenterology, Presbyterian Hospital of Dallas

Kimberly M. Persley, M.D., has no commercial relationships with manufacturers of products or providers of services discussed in this chapter.

Rajeev Jain, M.D., F.A.C.P., is an advisor or consultant for AstraZeneca Pharmaceuticals LP.

November 2005

Gallstone and biliary tract diseases constitute a common and costly health problem in the United States.1 The prevalence of gallstones increases with age in all racial groups. Increased body weight, rapid weight loss, pregnancy, alcoholic cirrhosis, and a family history of gallstone disease also appear to be risk factors.2,3,4

Incidence and Prevalence of Gallstones

In one epidemiologic study of persons 30 years of age and older, new gallstones were found to develop in 2.2% of men and 2.9% of women over a 5-year period.2 In the United States, gallstones occur in approximately 10% of persons older than 40 years, but the prevalence is significantly higher in women, increasing to 20% to 25% in women older than 50 years. Fortunately, only 20% to 30% of gallstones are symptomatic, with biliary colic being the most common symptom. A report from the Third National Health and Nutrition Examination Survey (NHANES III) stated that an estimated 6.3 million men and 14.2 million women 20 to 74 years of age had gallbladder diseases.5

Gallstone Formation

Two principal types of stone, the cholesterol stone and the pigment stone, form in the gallbladder and biliary tract. The cholesterol stone is composed mainly of cholesterol (> 50% of stone composition) and comprises multiple layers of cholesterol crystals and mucin glycoproteins. Mixed gallstones contain 20% to 50% cholesterol. The pigment stone contains a wide variety of organic and inorganic components, including calcium bilirubinate (40% to 50% of dry weight). In Europe and the United States, 90% of gallstones are of the cholesterol or mixed type; the remainder are pigment gallstones. Multiple risk factors for cholesterol and pigment gallstone formation have been identified [see Table 1]. In cholesterol gallstone formation, a genetic predisposition has been proposed on the basis of murine models and epidemiologic studies that show ethnic and geographic differences, as well as familial clustering of cholesterol gallstone disease.6

Table 1 Risk Factors for Cholesterol and Pigment Gallstone Formation

Cholesterol Gallstones

Pigment Gallstones

Increasing age

Increasing age

Female gender

Chronic hemolysis

Obesity

Alcoholic liver disease

Rapid weight loss

Biliary infection

Native-American heritage

Asian heritage

Hyperalimentation (gallbladder stasis)

Hyperalimentation (gallbladder stasis)

Elevated triglyceride levels

Duodenal diverticulum

Medications (e.g., fibric acid derivatives, estrogens, octreotide)

Truncal vagotomy

Ileal disease, resection, or bypass

Primary biliary cirrhosis

PIGMENT GALLSTONE FORMATION

The pathogenesis of pigment gallstones is not completely understood, but bacteria may play a central role.7 Black pigment stones are most often seen in patients with cirrhosis or hemolytic anemia and are found predominantly in the gallbladder. Brown pigment stones, which are common in Asians, are the most common stone to appear de novo in the bile duct and are associated with biliary tract infection. The prevalence of gallstones and gallbladder disease in Asians ranges from 5% to 20%.8 Pigment stones, in contrast to cholesterol stones, are often radiopaque and can be seen on plain abdominal x-rays [see Figure 1].

 

Figure 1. Radiograph: Radiopaque Stones

Radiograph of the right upper abdominal quadrant showing radiopaque stones in the gallbladder (small arrow) and common bile duct (large arrow).

CHOLESTEROL GALLSTONE FORMATION

Cholesterol is a minor but clinically significant component of bile. The other components of bile are bile salts, phospholipids, conjugated bilirubin, fatty acids, water, electrolytes, and other organic and inorganic substances. Cholesterol is a hydrophobic molecule that is relatively insoluble in water and precipitates unless it is maintained in solution by bile salts. Bile salt molecules possess hydrophilic (water-soluble) and hydrophobic (fat-soluble) regions that maintain cholesterol in a soluble state.

When bile salt molecules in water reach concentrations of 2 to 4 mM, they form spherical complexes called micelles; the concentration at which micelles form is known as the critical micellar concentration. In micelles, the negatively charged hydrophilic ends of the molecules face outward, toward the water, and the uncharged hydrophobic regions face the center of the sphere, toward one another. Cholesterol molecules are enclosed in the hydrophobic interiors.

A pure bile salt micelle must comprise at least 50 molecules to enclose a single molecule of cholesterol. The intercalation of phospholipids (principally lecithin) between bile salt molecules of a micelle improve the efficiency with which the micelle solubilizes cholesterol. Such a mixed micelle [see Figure 2], which is the type that exists in bile, needs only seven bile salt molecules to solubilize one cholesterol molecule. Free bile salt molecules exist in equilibrium with mixed micelles in a water solution. The combined molar concentration of bile salt and phospholipid is about 11 times that of cholesterol.

 

Figure 2. Mechanism of Gallstone Formation

Cholesterol is solubilized in bile by the formation of mixed micelles that consist predominantly of bile salt and phospholipid. Micelles form when the concentration of bile salts in water is between 2 and 4 mM, the so-called critical micellar concentration (CMC). The negatively charged hydrophilic region of the bile salt molecule faces outward into the water phase, whereas the uncharged hydrophobic region is directed inward. These three components—bile salts, phospholipids, and cholesterol—exist in equilibrium between the free state and micelle constituents. At the CMC for bile salts, the equilibrium shifts strongly in the direction of the micelle. If bile salt concentrations are insufficient, the hydrophobic cholesterol molecules will precipitate to form a nidus for a gallstone.

Cholesterol Saturated Bile

Cholesterol gallstone formation is potentiated by hepatic secretion of bile containing excess cholesterol relative to the concentration of bile salt.3,9 This occurs most often because of an increase in the biliary concentration of cholesterol but may also result from decreased bile acid secretion in certain disease states. Excess cholesterol is solubilized in micelles and in vesicles composed of phospholipid bilayers. Cholesterol crystal formation seems to occur at the surface of these vesicles.

Nucleation of Crystals and Gallbladder Stasis

In addition to supersaturated bile, nucleation of crystals and gallbladder stasis are also important factors in gallstone formation. Microscopic crystals initially precipitate from a supersaturated bile in a process called nucleation, which is influenced by several pronucleating and antinucleating proteins.3,9 Protein mucins, which are secreted by the gallbladder, and calcium are crucial promoters of the nucleation process. Prostaglandins stimulate the synthesis and secretion of mucins. Antinucleating factors, such as certain apolipoproteins, have been less well studied. Gallbladder stasis, with concentration and acidification of bile, is also an important factor in gallstone formation, promoting the growth of cholesterol crystals into stones. Cholesterol stones rarely recur in patients after cholecystectomy.

Development of Biliary Sludge

Biliary sludge (or microlithiasis) is a term that is often applied to cholesterol crystals of sufficient number to be visualized on ultrasonography.10 Biliary sludge, the precursor of most gallstones, is a mix of mucus, cholesterol monohydrate microcrystals, and calcium bilirubinate granules.4 Gallbladder sludge has been shown to precipitate biliary colic, acute cholecystitis, or pancreatitis and should be regarded as part of the spectrum of gallstone disease.

Gallbladder sludge and gallstones occur in 10% of women during pregnancy and in the early postpartum period, with significant spontaneous regression.11 Gallbladder sludge is also associated with fasting, rapid weight loss, parenteral nutrition, cirrhosis, and certain medications, such as ceftriaxone, cyclosporine, and octreotide.10

Choledocholithiasis

Common bile duct stones may form de novo in bile ducts (so-called primary choledocholithiasis, constituting 5% of bile duct stones) or migrate from the gallbladder to the biliary tract (secondary choledocholithiasis, constituting 95% of bile duct stones). Stones in the biliary tract usually have the same composition as those in the gallbladder, although some are softer and brownish. The brown color is a result of deposition of calcium bilirubinate and other calcium salts as a result of bacterial deconjugation of bilirubin and hydrolysis of phospholipids.

Cholecystitis and Cholelithiasis

Patients who have stones in the gallbladder or the biliary tree display syndromes that range from acute disease to chronic symptomatic or silent disease. Gallstone disease (cholelithiasis) may remain silent throughout a person's lifetime. At any stage of disease, obstruction of the cystic duct or common bile duct by a gallstone that has passed from the gallbladder may cause pain, with or without acute inflammation (cholecystitis).

SYMPTOMATIC CHOLELITHIASIS

With the exception of biliary colic, most symptoms of gallstones are not specific for gallstone disease; a meta-analysis indicated that 80% of patients with gallstones presented with other abdominal symptoms.12 Biliary colic is a misnomer, because the pain is steady and not colicky. The pain of biliary colic is caused by functional spasm of the cystic duct obstructed by a stone. Biliary colic often develops without any precipitating events. Typically, the pain is localized to the epigastrium, has a sudden onset, and increases rapidly in intensity to a plateau that can last as long as 3 hours before subsiding. Some patients describe the pain as excruciating or lancinating, whereas others describe it as a deep ache or cramp. The pain may radiate to the interscapular region or to the right shoulder, and it may be associated with nausea or vomiting. The pain is less frequently located in the left upper quadrant, precordium, or lower abdomen. Pain lasting longer than 6 hours or pain that is associated with fever suggests acute cholecystitis. Gastrointestinal symptoms, such as dyspepsia, heartburn, bloating, and fatty-food intolerance, are common whether or not gallstones are present. Thus, the diagnosis of biliary colic is based on clinical judgment. Once an episode of biliary colic has occurred, repeated attacks of pain are common.

ACUTE CHOLECYSTITIS

Acute cholecystitis refers to a syndrome of abdominal pain, fever, and leukocytosis associated with gallbladder inflammation, which is usually related to gallstone disease. Cholelithiasis is present in 90% to 95% of patients with acute cholecystitis, and most patients have had previous attacks of biliary colic. Acute cholecystitis may present as an acalculous cholecystitis in 5% to 10% of patients. It is predominantly noted in older men who are critically ill after major surgery, severe trauma, or extensive burn injury.13 In rare cases, acute cholecystitis can result from a specific infection, such as that caused by Salmonella species. Salmonella organisms can also colonize the gallbladder epithelium without inflammation (carrier state). Cytomegalovirus and crytosporidia can infect the biliary system, resulting in cholecystitis or cholangitis in immunocompromised patients, such as those with AIDS or those who have undergone bone marrow transplantation.

Diagnosis

Clinical manifestations

An episode of prolonged right upper quadrant pain (> 6 hours), especially if associated with fever, should arouse suspicion of acute cholecystitis, as opposed to simple biliary colic. Clinical features of acute cholecystitis include anorexia, nausea, vomiting, fever, and abdominal pain that initially may localize to the epigastrium before shifting to the right upper quadrant. The severe abdominal pain associated with acute cholecystitis is caused by inflammation of the gallbladder wall.9 Most patients who present with jaundice have stones in the common bile duct. Patients are ill for several days to a week before the acute attack completely subsides. Acalculous cholecystitis, an acute necroinflammatory disease, is clinically identical to acute cholecystitis but is not associated with gallstones.

Physical examination

Physical examination may reveal upper quadrant subcostal tenderness and pain on inspiration, often with inspiratory arrest (the Murphy sign). Of all physical examination findings, the Murphy sign has the highest positive likelihood ratio (LR) for acute cholecystitis (LR, 2.8; 95% confidence interval [CI], 0.8 to 8.6).14 The gallbladder may be palpable, especially at the time of the first attack, before fibrosis has reduced its distensibility. Tenderness, guarding, and rebound pain in the area of an inflamed gallbladder are important findings. Generalized rebound tenderness in a patient who has been ill for several days may reflect a perforation; however, localized tenderness may indicate secondary pancreatitis or an abscess in the area of the gallbladder.

Laboratory evaluation

Laboratory tests frequently reveal leukocytosis and mild hyperbilirubinemia, which may occur in the absence of biliary obstruction secondary to reduced hepatic excretion of bile.15 In one prospective study, 25% of patients with acute cholecystitis had a serum bilirubin level of 2 to 5 mg/dl and had no common bile duct abnormalities; 4% had an elevated amylase level without pancreatitis.16 No single laboratory parameter has a sufficient positive or negative LR to establish the diagnosis of acute cholecystitis or rule it out.14

Imaging studies

Acute cholecystitis should be suspected when a patient presenting with certain clinical manifestations (see above) is found to have gallstones on an imaging study. However, the mere presence of gallstones is not confirmation of acute cholecystitis, because asymptomatic cholelithiasis [see Asymptomatic Cholelithiasis, below] is a common condition in the general population. Ultimately, the combination of physical findings and laboratory results suggests the diagnosis of acute cholecystitis, which can then be confirmed by diagnostic imaging.14

Transabdominal ultrasonography (TUS) is the diagnostic procedure of choice for a patient with suspected gallstones and acute cholecystitis. Meta-analysis indicates that TUS has a sensitivity of 88% to 90% and a specificity of 97% to 98% for the diagnosis of gallstones larger than 2 mm.17 Gallbladder ultrasonography should ideally be preceded by an 8-hour fast, because gallstones are best visualized in a distended, bile-filled gallbladder. In addition to detecting gallstones, TUS can be used to identify other causes of right upper quadrant pain, such as hepatic abscess or malignancy, and it may reveal biliary duct obstruction. However, specific evidence of acute cholecystitis (i.e., the presence of pericholecystic fluid, edema of the gallbladder wall, or both) is found infrequently. Occasionally, a sonographic Murphy sign will be elicited when the ultrasound probe is positioned below the right costal margin.

Cholescintigraphy is the best method of confirming the clinical diagnosis of acute cholecystitis.17 This procedure takes only 60 to 90 minutes and involves the intravenous injection of technetium-99m (99mTC)—labeled hepatoiminodiacetic acid (HIDA, or lidofenin), which is selectively excreted into the biliary tree and enters the gallbladder. In the presence of acute cholecystitis, radiolabeled material enters the common bile duct and duodenum but not the gallbladder. Meta-analysis suggests that radionuclide scanning is the most accurate method of diagnosing acute cholecystitis.17 Occasionally, the scan gives false positive results in patients who have alcoholic liver disease or who are fasting or receiving total parenteral nutrition; however, false negative results are rare. Radionuclide scanning may not be useful for patients with deep jaundice, because the labeled agent fails to enter the biliary tree.

Direct examination of bile is more sensitive than ultrasonography in the diagnosis of biliary sludge. Ideally, gallbladder bile, rather than hepatic and ductal bile, should be obtained to maximize sensitivity for detecting microlithiasis; gallbladder bile is most reliably obtained by cholecystokinin-induced stimulation of the gallbladder [see Chronic Cholecystitis, Bile Collection and Examination, below]. Bile collected at endoscopic retrograde cholangiopancreatography (ERCP) after the injection of contrast may lead to false positive findings of crystals.18 Bile must be centrifuged and examined under polarizing or light microscopy for detection of crystals. Plain abdominal x-rays are much less useful than cholescintigraphy or ultrasonography, because only 15% to 20% of stones are radiopaque; oral cholecystography is also less useful and is now rarely performed because it requires 24 to 48 hours to perform and is less accurate than ultrasonography.

Differential Diagnosis

Because no single clinical or laboratory measurement carries sufficient weight to establish or exclude the diagnosis of acute cholecystitis,14the differential diagnosis is broad; it includes diseases that are characterized by severe epigastric symptoms and transient abnormal results on liver function testing.

Severe acute viral hepatitis or alcoholic hepatitis may be associated with moderately severe right upper quadrant pain, fever, and leukocytosis. A history of acute alcoholism, the finding of an enlarged liver, or markedly elevated aminotransferase levels should help distinguish one of these diagnoses from acute cholecystitis.

A patient with a penetrating or perforating ulcer may have severe epigastric pain and usually has a history of ulcer; free air may be evident on a plain abdominal x-ray if the ulcer has perforated. Early in its course, acute appendicitis may produce symptoms similar to those of acute cholecystitis, particularly if the appendix is retrocecal or the cecum is malpositioned in the subhepatic area. Acute pyelonephritis of the right kidney may produce anterior pain similar to the pain that occurs with acute cholecystitis. Pneumonia or infarction of the right lung may also cause abdominal symptoms.

Acute pancreatitis may be nearly impossible to distinguish from acute cholecystitis. Patients with either disorder may exhibit moderate signs on physical examination, with tenderness or localized rebound pain in the epigastrium. Serum amylase and lipase levels can be high in either condition, but the higher these enzyme levels are, the more likely it is that pancreatitis is present. Cholelithiasis occasionally causes pancreatitis, which further complicates the diagnosis. At times, only the clinical course distinguishes pancreatitis from cholecystitis.

Treatment

Medical therapy

Patients with a clinical diagnosis of acute cholecystitis should not be fed and should be given intravenous fluids and electrolytes. It is usually necessary to give a narcotic analgesic such as morphine or meperidine to alleviate severe pain. Febrile patients who have leukocytosis or bandemia (elevated circulating band forms) should be given a broad-spectrum antibiotic, such as a third-generation cephalosporin or, for broader coverage against Enterococcus, ampicillin-sulbactam or piperacillin-tazobactam. Nasogastric tube decompression may be required in patients who present with vomiting or with evidence of an ileus. The usual course is one of gradual improvement for several days. Persistence of severe symptoms may indicate pericholecystic abscess or perforation.

Surgery

In acute cholecystitis, laparoscopic cholecystectomy should be performed within 96 hours of onset of symptoms because the increasing inflammatory changes that occur over time have been implicated in bile duct injury; these changes may necessitate converting the procedure to an open cholecystectomy.19,20 Early laparoscopic cholecystectomy is recommended for acute cholecystitis, because a delay in surgery does not reduce morbidity, mortality, rate of conversion to open surgery, or mean hospital stay.21,22 In skilled hands, the laparoscopic procedure carries approximately the same risk as that of open cholecystectomy, but it is associated with much less postoperative pain and a shorter convalescence.19 In patients with cirrhosis, laparoscopic cholecystectomy is performed for more emergent reasons and is associated with higher morbidity; however, the laparoscopic approach offers advantages of less blood loss, shorter operative time, and shorter length of hospitalization in patients with compensated cirrhosis.23 In addition, laparoscopic cholecystectomy can be safely performed during pregnancy.24 Laparoscopic cholecystectomy is less expensive than minilaparotomy or open cholecystectomy in high-volume surgery.25

In the United States, approximately 75% of all cholecystectomies are performed laparoscopically; in 5% to 10% of these patients, the procedure has to be converted to open cholecystectomy.26 The complication rate of laparoscopic cholecystectomy is less than 5%, which is comparable to the rate reported for conventional cholecystectomy. Complications of laparoscopic cholecystectomy (bleeding and injury to the common bile duct, vasculature, and bowel) are more common when the surgeon is inexperienced.27 Although mortality appears to be lower for laparoscopic cholecystectomy than for open cholecystectomy, the total number of cholecystectomy-related deaths has not decreased over the years, because more procedures are being performed.28,29,30 This suggests that the benefits of laparoscopic cholecystectomy have expanded the indications for cholecystectomy.

Cholangiography can be performed during laparoscopic biliary surgery. However, because 10% to 15% of patients with acute cholecystitis have common duct stones, the physician should consider preoperative ERCP in patients with suspected choledocholithiasis (e.g., patients with jaundice, cholangitis, or a dilated common bile duct, as seen on ultrasonography).31 Common duct stones can be removed endoscopically. If endoscopic common duct stone removal is not possible, the operative procedure of choice is cholecystectomy, either open or laparoscopic, for common bile duct exploration and stone removal.

Some patients (e.g., patients with septic shock, peritonitis, severe pancreatitis, portal hypertension, or marked clotting disorders) are not candidates for laparoscopic cholecystectomy. These patients should generally undergo either open cholecystectomy, if their condition permits, or simple cholecystostomy. Cholecystostomy, either operative or percutaneous under ultrasound guidance, involves extracting the stones and draining the biliary tree through a catheter left in the gallbladder. Percutaneous cholecystostomy is superior to gallbladder aspiration in severe acute cholecystitis.32 Cholangiography can be carried out later through this drainage catheter. For patients who respond to cholecystostomy and improve enough to become candidates for elective surgery, interval cholecystectomy is recommended, because the risk of recurrent symptoms is significant.20

Surgery is contraindicated for some patients because of the presence of other serious medical problems. In these cases, conservative medical therapy, including the use of antibiotics, may be the only possible approach for the acute attack.

Complications

The major complications of acute cholecystitis are related to severe inflammation and necrosis of gallbladder tissue.33 Jaundice in the absence of choledocholithiasis can be noted in 15% of patients with acute cholecystitis; the stone impacted in the cystic duct results in edema and swelling, leading to extrinsic compression of the common hepatic duct, the common bile duct, or both [see Mirizzi Syndrome,below].34

Localized perforation and abscess

Localized perforation and abscess formation are commonly found in patients who have severe symptoms that persist for many days. Such patients usually show localized right upper quadrant tenderness and rebound pain. In patients who have a delayed or subacute presentation, perforation typically occurs in the gallbladder fundus, as a consequence of ischemia that leads to gangrene and necrosis.35 In patients who present with acute symptoms, the clinical differentiation between uncomplicated cholecystitis and gallbladder perforation is difficult; in this setting, ultrasonography should be the initial diagnostic modality.36 These patients often have diabetes or other immuncompromising conditions; therefore, acute symptoms in diabetic or immunocompromised patients may heighten the suspicion for perforation. Free perforation extending into the peritoneum occurs in 2% to 10% of patients with acute cholecystitis; it is associated with peritonitis and a mortality of 10% to 30%.37

Empyema

Empyema of the gallbladder occurs in 2% to 3% of patients with acute cholecystitis.38 Typically, abdominal pain is severe and lasts for more than 7 days. The physical examination is not distinctive. Mortality approaches 25%; death often occurs as a result of septicemia.

Emphysematous cholecystitis

Emphysematous cholecystitis, which has a higher morbidity than uncomplicated acute cholecystitis, is usually caused by gas-forming bacteria, such as Clostridium perfringens and other clostridia, Escherichia coli, or anaerobic streptococci. Patients who have such infections are often very ill, and up to 50% also have diabetes.35 Emphysematous cholecystitis occurs three times more often in men than in women.39Many cases of this type of cholecystitis are not associated with cholelithiasis. An ultrasound or computed tomography scan frequently reveals gas within the gallbladder; however, one study indicated that a plain abdominal x-ray is not sensitive as a diagnostic study in emphysematous cholecystitis [see Figure 3].39

 

Figure 3. CT: Emphysematous Cholecystitis

CT scan from an elderly man with nausea and abdominal pain following an acute myocardial infarction, angioplasty, and stent placement. The scan shows air in the wall of the gallbladder and an air-fluid level within the gallbladder, diagnostic of emphysematous cholecystitis. The patient was treated with antibiotics and a percutaneous cholecystostomy tube; laparoscopic cholecystectomy was planned in a few months.

Cholecystenteric fistula

Another possible complication of acute cholecystitis is a cholecystenteric fistula, in which the gallbladder is connected either to the duodenum or to the hepatic flexure of the colon. In rare cases, the gallbladder communicates directly with the stomach or jejunum. A large gallstone (> 2.5 cm in diameter) will erode through the gallbladder wall into the duodenum. Subsequently, the stone may become impacted at the terminal ileum, causing small bowel obstruction, or in the duodenal bulb, resulting in gastric outlet obstruction (Bouveret syndrome). A cholecystenteric fistula is suspected when a plain abdominal x-ray shows pneumobilia, an ectopic stone, and mechanical obstruction. A barium upper gastrointestinal series can delineate a fistulous tract between the gallbladder and the intestines. CT scanning can define the site of obstruction and visualize the cholecystenteric fistula in 11% of patients.40 Treatment of cholecystenteric fistula usually consists of one-stage cholecystectomy, exploration of the common bile duct, closure of the fistula, and extraction of the impacted stone.

Gallstones and malignancy

Gallstones are present in 65% to 90% of patients with gallbladder cancer, although it is not clear whether gallstones themselves are the causal factor in oncogenesis.41 A palpable gallbladder is usually found in malignant obstruction of the common bile duct (Courvoisier's law); however, this sign is uncommon in cases in which obstruction is caused by gallstones.

CHRONIC CHOLECYSTITIS

Chronic cholelithiasis is usually accompanied by evidence of chronic cholecystitis. The wall of the gallbladder is often thickened, fibrotic, and rigid, and the gallbladder is thus prevented from contracting and expanding normally. This condition may arise from a series of attacks of acute cholecystitis, from chronic mechanical irritation by calculi, or from both. The gallbladder wall may calcify and appear as the so-called porcelain gallbladder on plain abdominal x-ray [see Figure 4].

 

Figure 4. Radiograph in Chronic Cholecystitis

Radiograph of the right upper abdominal quadrant during upper GI barium study showing a calcified wall of the gallbladder (“porcelain” gallbladder), indicating chronic cholecystitis and a high risk of gallbladder cancer.

Diagnosis

Clinical manifestations

It is difficult to attribute any symptom to chronic cholecystitis per se. Complaints of flatulence, heartburn, and nonspecific postprandial distress are common in patients with chronic cholecystitis, but such symptoms are also common in patients with no evidence of gallbladder disease. It is possible, however, to elicit a history of discrete attacks of abdominal pain resembling those of acute cholecystitis.

Physical examination

Findings on physical examination are usually normal unless the patient is experiencing an acute attack of cholecystitis. The gallbladder is rarely palpable because scarring associated with chronic cholecystitis prevents expansion.

Laboratory evaluation

Results of routine laboratory tests are usually normal; occasionally, the serum alkaline phosphatase level is modestly elevated.

Imaging studies

TUS is the procedure of choice for the diagnosis of chronic gallbladder disease. In 90% to 95% of cases of cholelithiasis, ultrasonography demonstrates the echo of the calculus and the acoustic shadow behind the calculus [see Figure 5]. When the ultrasound is nondiagnostic, oral cholecystography may still be used to evaluate a patient with suspected gallbladder disease. If a double dose of the oral contrast agent fails to cause gallbladder opacification, cholelithiasis and chronic cholecystitis are almost certainly present. Cholescintigraphy is not helpful in diagnosing chronic cholelithiasis or chronic cholecystitis [see Acute Cholecystitis, above].

 

Figure 5. Ultrasound of Gallbladder

Ultrasound of the gallbladder showing, in the center of the image, a stone within the gallbladder with a triangular area of acoustic attenuation (“shadowing”) behind the gallstone.

ERCP may reveal gallstones in the gallbladder of patients who have biliary tract pain and whose oral cholecystograms and gallbladder sonograms are normal. In one study, small gallstones were found with ERCP in 29 of 206 such patients (14%); the presence of these stones was confirmed during surgery.42 CT or magnetic resonance imaging may also detect gallstones, but these techniques are unlikely to demonstrate stones not detected by ultrasonography. Endoscopic ultrasonography (EUS), with or without duodenal bile aspiration, may be a promising diagnostic approach in patients who have typical biliary symptoms but normal findings on transabdominal ultrasound.43,44,45

Bile collection and examination

Gallbladder bile can be obtained by nasogastric tube or by endoscopic aspiration of the duodenum after infusing cholecystokinin intravenously to promote gallbladder emptying. In patients with biliary sludge, examination of bile under light and polarizing microscopy can show cholesterol crystals, which appear as rhomboid plates with a notch in one corner. Bile collected from the common bile duct during ERCP rarely contains precipitate, because hepatic bile transits rapidly through the biliary system,10 and injection of contrast can lead to false positive results.18 In one small study, EUS-guided aspiration of gallbladder bile was complicated by bile peritonitis in two of three patients.46 Although some experts consider bile microscopy to be a gold standard in the diagnosis of biliary sludge, crystal analysis is limited by the need for invasive evaluation, meticulous sample processing, and institutional expertise.

Treatment

Surgery

Elective cholecystectomy is indicated for patients who have symptomatic gallstones and chronic cholecystitis. Recurrent pain is to be expected in these patients if cholecystectomy is not performed. As many as 50% of patients with symptomatic gallstones who do not undergo cholecystectomy experience serious complications within 20 years after initial onset of symptoms.47

It is occasionally difficult to determine whether abdominal symptoms are secondary to documented gallbladder disease. A history of typical recurrent pain makes this determination easier. In certain cases, elective cholecystectomy is performed as a last diagnostic procedure when a thorough search for other causes of abdominal symptoms has proved negative. All too often, the symptoms recur postoperatively.

Dissolution therapy

Oral bile acids, such as ursodeoxycholic acid (8 to 12 mg/kg daily) and chenodeoxycholic acid (13 to 15 mg/kg daily), can decrease biliary cholesterol levels; and when administered for months to years, ursodeoxycholic acid and chenodoxycholic acid can result in complete gallstone dissolution in 30% and 14% of patients, respectively.48 A randomized, controlled trial found that combination therapy using these two agents was not superior to monotherapy with ursodeoxycholic acid.49 Chenodeoxycholic acid has largely been replaced by the safer ursodeoxycholic acid; however, these drugs are effective only in patients with small cholesterol stones and a functioning gallbladder. A high rate of gallstone recurrence is noted after cessation of therapy. Infusing methyl tert-butyl ether through a transhepatic catheter directly into the gallbladder can rapidly dissolve cholesterol stones.50 The rapid infusion and removal of this ether, which remains liquid at body temperature, results in the dissolution of most cholesterol gallstones within 4 to 31 hours. Dissolution therapy has limited value, except in patients who are poor candidates for surgery.

Extracorporeal biliary lithotripsy

Stones in the gallbladder or common bile duct have been successfully fragmented using extracorporeal shock wave lithotripsy (ESWL), a technique widely employed for the nonsurgical fragmentation of kidney stones. Patients undergoing biliary ESWL are carefully positioned and monitored so that the shock waves are targeted at the gallstones. The highest success rates of biliary ESWL are seen in patients with a radiolucent solitary gallstone less than 2 cm in diameter; 60% to 84% of these patients are free of stones after 6 to 12 months of therapy.51 ESWL has been associated with low rates of adverse events such as pancreatitis, biliary pain, hepatic hematoma, and hematuria. The administration of oral ursodeoxycholic acid after fragmentation of stones has been associated with an increase in the percentage of patients who are free of gallbladder stones 6 months after ESWL.52,53 In one study, 21% of patients who received 10 to 12 mg/kg of ursodeoxycholic acid daily for 6 months after ESWL were free of gallbladder stones at the end of the treatment period; in contrast, only 9% of patients who received placebo for 6 months were free of stones.53 Stone fragments in the common bile duct may pass spontaneously after endoscopic sphincterotomy or can be extracted with a basket. The usefulness of biliary ESWL is limited by its high rate of gallstone recurrence and the widespread availability of laparoscopic cholecystectomy.

ASYMPTOMATIC CHOLELITHIASIS

Most gallstones are asymptomatic (silent gallstones). In one prospective study, gallstones were present or there was evidence of cholecystectomy in 291 of 1,701 persons (17%) at the time of postmortem examination.54 Of these 291 persons, only 31 had undergone cholecystectomy, presumably because of symptomatic disease. Ten deaths were directly attributable to the gallstones; four of these deaths occurred after cholecystectomy.

Natural History

Silent gallstones seldom lead to problems. In a long-term follow-up study of patients with asymptomatic gallstones, the cumulative risk of the development of symptoms was 10% at 5 years, 15% at 10 years, and 18% at 15 years or later.55 Nineteen percent of patients who experienced symptoms (2.5% of the patients enrolled in the study) subsequently developed acute cholecystitis or pancreatitis. No patients died of gallbladder disease during a mean follow-up period of more than 10 years.

Diagnosis

Asymptomatic gallstones are usually identified incidentally on transabdominal or pelvic ultrasonography performed for other diagnostic purposes, such as the evaluation of gynecologic symptoms or findings on physical examination.

Treatment

Patients who have asymptomatic gallstones should generally be managed conservatively without surgery. Exceptions may be made for patients at increased risk for gallbladder cancer, such as Pima Indians, patients with calcified gallbladders (porcelain gallbladder), patients with very large gallstones (> 3 cm), and patients with an associated gallbladder polyp greater than 10 mm in diameter.56

In the past, prophylactic cholecystectomy was recommended for diabetic patients who had asymptomatic gallstones; anecdotal reports suggested that such patients did poorly when cholecystectomy was performed as an emergency procedure. However, two well-controlled, retrospective studies of patients undergoing surgery for acute cholecystitis and a decision analysis showed that diabetes was not an independent risk factor of operative mortality or serious postoperative complications, and prophylactic cholecystectomy resulted in a shortened life span.57,58 Thus, prophylactic cholecystectomy cannot be recommended for patients with diabetes.

CHOLEDOCHOLITHIASIS

Choledocholithiasis, a condition in which a stone lodges in the common bile duct after passage from the gallbladder through the cystic duct, develops secondary to chronic cholelithiasis in 15% to 20% of patients.9,59 Primary common bile duct stones are more commonly seen in Asian populations than in populations of the Western world. This increased incidence of primary common bile duct stones is attributed to the increased prevalence of flukes and parasitic infections (e.g., clonorchiasis, fascioliasis, and ascariasis) in Asia, because of the prevalent use of uncooked seafood in the diet. Other risk factors for choledocholithiasis include the presence of periampullary diverticula and advancing age.60

Diagnosis

Clinical manifestations

The signs and symptoms associated with choledocholithiasis vary. Some patients have no symptoms, whereas others may present with an acute illness. Pain is a common feature and is often located in the right upper quadrant or midepigastrium, with radiation of the pain to the interscapular region. Pain may be associated with nausea, vomiting, or both; it can be indistinguishable from biliary colic. Cholangitis may present as the Charcot triad (fever, pain, and jaundice) or the Reynold pentad (Charcot triad of symptoms, hypotension, and a change in mental status). Patients may also present with pancreatitis.

Physical examination

Vital signs may reveal an elevated temperature. In more acutely ill patients, hypotension and tachycardia may occur. Physical exam may reveal tenderness and guarding in the right upper quadrant and midepigastrium. Hepatomegaly may be found when common bile duct obstruction has been present for some time. Scleral icterus may also be seen.

Laboratory evaluation

Both serum bilirubin and alkaline phosphatase levels can be markedly elevated. However, when the stones do not obstruct the duct, the serum bilirubin level may be only slightly elevated or may be normal, and the alkaline phosphatase level may be substantially elevated. Typically, serum aminotransferase levels are only modestly elevated. It would be unusual to see aminotransferase levels higher than 1,000 IU/L. In some instances, aminotransferase levels rise and fall rapidly early in the course of bile duct obstruction.

Imaging studies

TUS may detect only 50% of common bile duct stones61; however, it can often detect dilatation of common bile duct and intrahepatic ducts. The sensitivity of TUS for detecting common duct stones increases to 76% when ductal dilatation of more than 6 mm is used as the primary end point for choledocholithiasis. CT is no more sensitive or specific than TUS. Cholescintigraphy may show common bile duct obstruction, particularly when symptoms are of recent onset, but not all common bile duct stones will cause complete bile duct obstruction. Magnetic resonance cholangiopancreatography (MRCP) and EUS have similar accuracies in detecting common bile duct stones. MRCP [see Figure 6] is noninvasive and may be preferred in cases where the suspicion of choledocholithiasis is mild to moderate.62,63

 

Figure 6. Magnetic Resonance Cholangiopancreatogram

This magnetic resonance cholangiopancreatogram shows multiple gallstones (arrows) in the common bile duct (choledocholithiasis).

ERCP allows radiographic visualization of the biliary tree [see Figure 7] and the option of therapeutic intervention.64,65 EUS has greater sensitivity and specificity than ERCP in the detection of common bile duct stones but lacks the therapeutic option available with ERCP.66Therefore, ERCP is the technique of choice if common bile duct stones are highly suspected on the basis of the history, physical examination findings, and laboratory and imaging studies. When ERCP is unavailable or is unsuccessful in detecting bile duct stones, percutaneous transhepatic cholangiography (PTC) allows for direct imaging of bile ducts and offers the potential for therapeutic intervention. PTC involves accessing the bile ducts via a small needle.67 The success rate of PTC in patients with dilated ducts is close to 100%; nondilated ducts are entered successfully about 70% of the time. Complication rates for both ERCP and PTC approach 5%. ERCP has replaced PTC as the technique of choice.

 

Figure 7. ERCP Showing Gallstones

Endoscopic retrograde cholangiopancreatography reveals abnormalities in a patient with gallstones. Multiple radiolucent areas establish the diagnosis of stones in the gallbladder (broken arrow) and common bile duct (solid arrow).

Treatment

Endoscopic sphincterotomy is the initial treatment for the patient with choledocholithiasis. In one large study, sphincterotomy was successful in 97.5% of patients with common bile duct stones, although more than one attempt was necessary in some patients. The overall rate of clearance of bile duct stones was 84.5%. The remaining patients required either surgery or permanent placement of a biliary endoprosthesis. The overall complication rate was 6.9%, and the complications included bleeding, cholangitis, pancreatitis, and perforation. The 30-day procedure-related mortality was 0.6%.68 Follow-up studies have shown a low rate of recurrence of biliary duct problems and a low incidence of papillary stenosis.69 Operative exploration of the common duct should be reserved for the few patients in whom endoscopic sphincterotomy is unsuccessful. Laparoscopic removal of biliary stones may be an alternative to preoperative ERCP.70,71

Endoscopic sphincterotomy is also the treatment of choice for patients with retained bile duct stones after gallbladder or biliary tract surgery. If sphincterotomy fails and if the patient has a T tube in place, instrumental extraction through the mature T-tube tract may be successful. Surgical exploration of the biliary tree is indicated if nonsurgical treatments fail.

MIRIZZI SYNDROME

Mirizzi syndrome refers to an obstruction of the common hepatic duct caused by a stone impacted at the neck of the gallbladder or the cystic duct. Mirizzi syndrome is classified into type I and type II.72 In Mirizzi syndrome type I, there is only an extrinsic compression of the common hepatic duct by the gallstone and accompanying inflammation. In Mirizzi syndrome type II, a cholecystocholedochal fistula is established by the mechanism of pressure-induced necrosis from the gallstone.

Diagnosis

The clinical presentation of individuals with Mirizzi syndrome varies greatly.73 Obstructive jaundice is commonly seen. However, 20% to 40% of patients may present without jaundice or have normal serum aminotransferase levels.74 Biliary imaging tests often fail to demonstrate the features of Mirizzi syndrome; therefore, successful management of patients with Mirizzi syndrome is a challenge and relies heavily upon clinical suspicion and early recognition by the treating physician.

Treatment

Nonsurgical treatment of Mirizzi syndrome is limited and suboptimal. Long-term biliary stenting has a relatively high incidence of complications, including cholangitis and secondary biliary cirrhosis.73 Nonsurgical lithotripsy and stone removal is restricted to patients with Mirizzi syndrome type II.75 In Mirizzi syndrome type I, the offending stones are not accessible for clearance via bile ducts. Cholecystectomy is the treatment of choice. If the gallbladder is not removed, patients with Mirizzi syndrome are left at significant risk for complications from continued gallstone disease, including acute cholangitis, cholecystitis, suppurative cholangitis, liver abscess, secondary biliary cholangitis, and, perhaps, gallbladder carcinoma.73,75,76 Nonsurgical treatment of patients with Mirizzi syndrome should be limited to those patients who are unfit for surgery or who have a shortened life expectancy.34

Chronic Biliary Tract Disease

Chronic inflammation of biliary ducts is usually caused by partial or complete obstruction of the biliary tree. Some patients with chronic cholelithiasis or other chronic diseases of the biliary ducts will experience associated chronic inflammation or stricturing of the biliary tree.

DIAGNOSTIC OVERVIEW

Clinical Manifestations

Patients with chronic inflammation of the biliary tree may complain of fatigue, intermittent fever and chills, anorexia, pruritus, and weight loss. The physical examination may be fairly unremarkable; jaundice, excoriations of the skin related to marked pruritus, and stigmata of chronic liver disease may raise the level of suspicion.

Laboratory Evaluation

Laboratory tests will often reveal chronically elevated serum alkaline phosphatase levels and increased levels of serum 5′-nucleotidase, leucine aminopeptidase, and γ-glutamyl transpeptidase (GGT). Transient elevations of the total bilirubin level may also been seen.

Imaging Studies

Direct visualization of the biliary tree is important in determining whether the symptoms and signs result from an anatomic defect that can be corrected by endoscopic therapy or surgery. Use of MRCP or ERCP usually leads to identification of the obstructive site.

SPECIFIC PRESENTATIONS

Common Bile Duct Stricture

Benign and malignant strictures are similar in appearance, as imaged by ERCP or MRCP. Epithelial samples of biliary strictures for evaluation can be obtained by brush cytology; fine-needle aspiration; endoscopic pinch biopsy; or a combination of the three. The sensitivity of brush cytology is as high as 70% for the diagnosis of a malignant stricture of the bile duct; specificity is as high as 100%.77 Simple bile duct aspiration alone is not as reliable. Common bile duct stricture, which may result from biliary tract surgery, can be treated endoscopically with balloon dilatation or with the placement of an endoprosthesis. If these treatments are unsuccessful, surgical intervention may prove beneficial for selected patients.

Primary Sclerosing Cholangitis

Primary sclerosing cholangitis (PSC) is a disease of unknown etiology that is characterized by an irregular inflammatory fibrosis of both the intrahepatic and extrahepatic bile ducts [see Figure 8].78 It usually occurs in men between 20 and 50 years of age.

 

Figure 8. Cholangiogram in Primary Sclerosing Cholangitis

This cholangiogram, obtained during endoscopic retrograde cholangiopancreatography, shows a normal gallbladder (black arrow) and a narrowed biliary tree with many areas of segmental stenosis (white arrows), diagnostic of primary sclerosing cholangitis.

Patients may present with jaundice, pruritus, nonspecific pain, fever, and weight loss. Approximately 75% of patients will have chronic ulcerative colitis. Liver function tests show cholestatic abnormalities.78

Ursodeoxycholic acid therapy will usually result in an improvement in the biochemical markers of cholestasis, but it has not been shown to increase survival.79 Endoscopic treatment of significant ductal strictures may also improve biochemical markers of cholestasis and reduce the number of episodes of cholangitis.80 A combined approach using therapeutic stricture dilatation and ursodeoxycholic acid therapy may benefit a select group of patients.

Patients with PSC are at increased risk for biliary tract cancer. The incidence of cholangiocarcinoma in patients with PSC is as high as 30%, and there is an increased risk of gallbladder and pancreatic cancer.81 A substantial number of patients with PSC may have undetected cholangiocarcinoma at the time of liver transplantation.

Recurrent Pyogenic Cholangitis

Recurrent pyogenic cholangitis (RPC), as its name suggests, is a condition characterized by recurrent bouts of inflammation of the bile ducts. It most commonly affects patients of Asian descent. The exact etiology of RPC is unclear. Some experts propose a dietary or infectious cause. The parasites Opisthorchis sinensis and Ascaris lumbricoides are commonly found in the stools of affected patients.82

Patients typically present with repeated attacks of fever, chills, abdominal pain, and jaundice. Laboratory tests usually demonstrate an elevation in serum bilirubin and alkaline phosphatase levels. Elevations in serum aminotransferase levels and the prothrombin time signify hepatocyte injury, although the prothrombin time may also be prolonged because of vitamin K malabsorption.83

Imaging studies, such as ultrasonography, may be somewhat confusing in patients with RPC, because there may be areas of intrahepatic biliary dilatation without common bile duct dilatation. Evaluation using CT or MRCP usually defines the areas of intrahepatic and extrahepatic biliary dilatation more clearly than does ultrasonography, and these techniques also provide three-dimensional information.84 ERCP is often required to confirm areas of stricture and dilatation. ERCP also allows for possible therapeutic intervention. PTC provides access to peripheral ducts that may be inaccessible by ERCP.85

Treatment usually consists of antibiotic therapy and endoscopic or surgical stone clearance to improve biliary drainage.

Choledochal Cyst

Biliary cystic disease includes choledochal cyst disease and the less common gallbladder cysts and cystic duct cysts.86 Choledochal cyst is an ectasia of the common bile duct that may present in late childhood or in adult life as obstructive jaundice. The cause of the disorder is not fully defined, and both congenital and acquired etiologies are postulated.87

Diagnosis

Clinical manifestations of choledochal cyst in children include abdominal pain, cholangitis, and an abdominal mass. A palpable mass is unusual in adults, because adults tend to present with recurrent cholangitis, pancreatitis, or, rarely, portal hypertension. Choledochal cysts may involve any segment of the bile duct and are categorized according to the classification proposed by Todani and colleagues [see Table 2].88 An abnormal pancreatobiliary duct junction is more common in patients with choledochal cysts and could expose the bile ducts to pancreatic juices, which could result in progressive injury to the ductal system. Type I cysts are the most common, accounting for 40% to 60% of all cases, followed by type IV. Types II, III, and V are rare.

Table 2 Modified Classification System for Choledochal Cysts and Surgical Procedure of Choice

Classification

Type

Procedure of Choice

Type IA

Choledochal cyst

 

Type IB

Segmented choledochal dilatation

Roux-en-Y hepaticojejunostomy

Type IC

Diffuse or cylindrical duct dilatation

 

Type II

Extrahepatic duct diverticulum

Excision of diverticulum

Type III

Choledochocele

Endoscopic sphincterotomy

Type IVA

Multiple intrahepatic and extrahepatic duct cysts

Roux-en-Y hepaticojejunostomy

Type IVB

Multiple extrahepatic duct cysts

 

Type V

Intrahepatic duct cysts (Caroli disease and Caroli syndrome)

Hepatic resection, liver transplantation

*All patients with choledochal cysts must undergo cholecystectomy to decrease the risk of malignancy, with the possible exception of patients with type III cysts. For the much rarer gallbladder and cystic duct cysts, treatment is cholecystectomy.

A combination of imaging studies may establish the diagnosis. Ultrasonography may delineate the cyst and intrahepatic portions of the disease. CT and MRCP may provide useful information in regard to the extent of disease and the potential for malignancy. ERCP, PTC, and intraoperative cholangiography are important for diagnostic evaluation and surgical planning.

Treatment

The initial treatment of choledochal cysts depends on the age of the patient, the presentation, and the type of the cyst. In terms of definitive treatment, pharmacologic or endoscopic management offers little benefit in that these forms of therapy do not address the well-described malignant potential of bile duct cysts.89 Therefore, the primary role of endoscopic procedures is in the initial evaluation and diagnosis of bile duct cysts. However, endoscopic interventions such as lithotripsy, stone extraction, and laser ablation have proved successful in the treatment of intrahepatic and extrahepatic biliary stones in patients with Caroli disease, a congenital disorder associated with renal cystic disease of varying severity.90 Endoscopic therapy, such as stone extraction, can be a definitive treatment for patients with recurrent pyogenic cholangitis. It would be the chosen therapy in elderly patients or in patients considered to be poor candidates for surgery. The current standard for surgical treatment in the patient who is a reasonable surgical risk is excision of the cyst with free biliary drainage into the gastrointestinal tract. The classical surgical reconstruction is a hepaticojejunostomy with a Roux-en-Y [see Table 2] reconstruction.91

Sphincter of Oddi Dysfunction

Sphincter of Oddi dysfunction (SOD) is a benign condition of intermittent or permanent obstruction of biliary drainage, pancreatic drainage, or both that is caused either by a stenosis or by smooth muscle dysfunction of the sphincter muscle.92 Biliary SOD is classified into three types on the basis of clinical parameters using the modified Milwaukee criteria [see Table 3].

Table 3 Clinical Classification System for Biliary-Specific Abdominal Pain Associated with SOD*

Criteria

1. Typical biliary-type pain

2. Elevated liver enzyme levels (AST, alkaline phosphatase, or both more than two times normal on at least two occasions)

3. Delayed drainage of contrast injection during ERCP (> 45 min)

4. Dilated common bile duct (> 12 mm)

Classification Based on above Criteria

·         Biliary type I: criteria A through D are present; SOD is present in 80%–90% of patients

·         Biliary type II: criterion A plus one or two other criteria are present; SOD is present in 50% of patients

·         Biliary type III: only criterion A is present; SOD is uncommon

* A similar classification for SOD and pancreatic-type abdominal pain exists but is not included in this table.
AST—aspartate aminotransferase  ERCP—endoscopic retrograde cholangiopancreatography  SOD—sphincter of Oddi dysfunction

Diagnosis

Biliary SOD is usually seen in women in the fourth to sixth decades of life. The symptoms arise typically after cholecystectomy, although SOD may occur in patients with an intact gallbladder.93,94 The clinical presentation of biliary SOD is episodic abdominal pain in the epigastric region or the right upper quadrant that may radiate to the back or shoulders. It may be associated with nausea or vomiting that worsens with eating. Laboratory tests may reveal elevated liver function. Right upper quadrant ultrasonography and CT may reveal a dilated common bile duct.

ERCP with sphincter of Oddi manometry is the gold standard for diagnosis of SOD. A basal sphincter pressure of more than 40 mm Hg is abnormal and indicative of SOD.95 Other tests that are noninvaive and less reliable may also indicate the presence of SOD; such tests include a provocation test with morphine (or neostigmine), which produces biliary pain and elevation of the serum aminotransferase level; ultrasound evaluation of dilatation and emptying of the common bile duct after secretin stimulation; or the kinetics of ductal emptying studied by scintigraphy.96

Sphincter of Oddi manometry is not required to confirm the diagnosis of type I SOD disease. However, patients classified with type II disease should undergo sphincter of Oddi manometry because only 50% of patients in this group have SOD. In patients classified as having type II disease, only patients whose SOD is confirmed by sphincter of Oddi manometry should undergo endoscopic sphincterotomy. Sphincter of Oddi manometry, endoscopic sphincterotomy, or both have low efficacy in patients with type III disease.

Treatment

A low-fat diet may decrease biliary or pancreatic stimulation, although the efficacy of this approach is unknown. Endoscopic sphincterotomy is the primary treatment for patients with SOD type I disease and for patients with types II and III disease in which the presence of SOD has been confirmed by manometry. Over 90% of patients with type I disease will have a favorable response to endoscopic sphincterotomy; therefore, manometry should not be performed in these patients.

Pharmacologic therapies (i.e., calcium channel blockers and nitrates) are primarily used in patients with type III disease, because in these patients, sphincter of Oddi manometry has the greatest risk of complication and the smallest diagnostic yield. Treatment with calcium channel blockers and nitrates decreases pain by relaxing the sphincter smooth muscle.92

Other endoscopic therapies such as balloon dilatation, injection of botulinum toxin, temporary stent placement, and surgical sphincteroplasty are not widely used in the treatment of SOD.97,98,99

Acknowledgments

Figure 1 Courtesy of William E. Stevens, M.D.

Figure 2 Alan Iselin.

Figure 3 Courtesy of Laura Thomas, M.D., and Mark Feldman, M.D.

Figures 4 and 5 Courtesy of Mark Feldman, M.D.

Figure 6 Courtesy of David Riepe, M.D.

Figures 7 and 8 Courtesy of Malcolm F. Anderson, M.D.

References

  1. Sandler RS, Everhart JE, Donowitz M, et al: The burden of selected digestive diseases in the United States. Gastroenterology 122:1500, 2002
  2. Jensen KH, Jorgensen T: Incidence of gallstones in a Danish population. Gastroenterology 100:790, 1991
  3. Donovan JM: Physical and metabolic factors in gallstone pathogenesis. Gastroenterol Clin North Am 28:75, 1999
  4. Ko CW, Sekijima JH, Lee SP: Biliary sludge. Ann Intern Med 130(4 pt 1):301, 1999
  5. Everhart JE, Khare M, Hill M, et al: Prevalence and ethnic differences in gallbladder disease in the United States. Gastroenterology 117:632, 1999
  6. Wang DQ, Afdhal NH: Genetic analysis of cholesterol gallstone formation: searching for Lith (gallstone) genes. Curr Gastroenterol Rep 6:140, 2004
  7. Stewart L, Oesterle AL, Erdan I, et al: Pathogenesis of pigment gallstones in Western societies: the central role of bacteria. J Gastrointest Surg 6:891, 2002
  8. Shaffer EA: Epidemiology and risk factors for gallstone disease: has the paradigm changed in the 21st century? Curr Gastroenterol Rep 7:132, 2005
  9. Johnston DE, Kaplan MM: Pathogenesis and treatment of gallstones. N Engl J Med 328:412, 1993
  10. Jain R: Biliary sludge: When should it ot be ignored? Curr Treat Options Gastroenterol 7:105, 2004
  11. Ko CW, Beresford SA, Schulte SJ, et al: Incidence, natural history, and risk factors for biliary sludge and stones during pregnancy. Hepatology 41:359, 2005
  12. Berger MY, van der Velden JJ, Lijmer JG, et al: Abdominal symptoms: do they predict gallstones? A systematic review. Scand J Gastroenterol 35:70, 2000
  13. Owen CC, Jain R: Acute acalculous cholecystitis. Curr Treat Options Gastroenterol 8:99, 2005
  14. Trowbridge RL, Rutkowski NK, Shojania KG: Does this patient have acute cholecystitis? JAMA 289:80, 2003
  15. Edlund G, Kempi V, van der Linden W: Jaundice in acute cholecystitis without common duct stones. Acta Chir Scand 149:597, 1983
  16. Kurzweil SM, Shapiro MJ, Andrus CH, et al: Hyperbilirubinemia without common bile duct abnormalities and hyperamylasemia without pancreatitis in patients with gallbladder disease. Arch Surg 129:829, 1994
  17. Shea JA, Berlin JA, Escarce JJ, et al: Revised estimates of diagnostic test sensitivity and specificity in suspected biliary tract disease. Arch Intern Med 154:2573, 1994
  18. Parasher VK, Romain K, Sukumar R, et al: Can ERCP contrast agents cause pseudomicrolithiasis? Their effect on the final outcome of bile analysis in patients with suspected microlithiasis. Gastrointest Endosc 51(4 pt 1):401, 2000
  19. Zacks SL, Sandler RS, Rutledge R, et al: A population-based cohort study comparing laparoscopic cholecystectomy and open cholecystectomy. Am J Gastroenterol 97:334, 2002
  20. Bhattacharya D, Ammori BJ: Contemporary minimally invasive approaches to the management of acute cholecystitis: a review and appraisal. Surg Laparosc Endosc Percutan Tech 15:1, 2005
  21. Shikata S, Noguchi Y, Fukui T: Early versus delayed cholecystectomy for acute cholecystitis: a meta-analysis of randomized controlled trials. Surg Today 35:553, 2005
  22. Papi C, Catarci M, D'Ambrosio L, et al: Timing of cholecystectomy for acute calculous cholecystitis: a meta-analysis. Am J Gastroenterol 99:147, 2004
  23. Puggioni A, Wong LL: A metaanalysis of laparoscopic cholecystectomy in patients with cirrhosis. J Am Coll Surg 197:921, 2003
  24. Barone JE, Bears S, Chen S, et al: Outcome study of cholecystectomy during pregnancy. Am J Surg 177:232, 1999
  25. Nilsson E, Ros A, Rahmqvist M, et al: Cholecystectomy: costs and health-related quality of life: a comparison of two techniques. Int J Qual Health Care 16:473, 2004
  26. Livingston EH, Rege RV: A nationwide study of conversion from laparoscopic to open cholecystectomy. Am J Surg 188:205, 2004
  27. See WA, Fisher RJ, Winfield HN, et al: Laparoscopic surgical training: effectiveness and impact on urological surgical practice patterns. J Urol 149:1054, 1993
  28. Legorreta AP, Silber JH, Costantino GN, et al: Increased cholecystectomy rate after the introduction of laparoscopic cholecystectomy. JAMA 270:1429, 1993
  29. Steiner CA, Bass EB, Talamini MA, et al: Surgical rates and operative mortality for open and laparoscopic cholecystectomy in Maryland. N Engl J Med 330:403, 1994
  30. Escarce JJ, Chen W, Schwartz JS: Falling cholecystectomy thresholds since the introduction of laparoscopic cholecystectomy. JAMA 273:1581, 1995
  31. Tse F, Barkun JS, Barkun AN: The elective evaluation of patients with suspected choledocholithiasis undergoing laparoscopic cholecystectomy. Gastrointest Endosc 60:437, 2004
  32. Ito K, Fujita N, Noda Y, et al: Percutaneous cholecystostomy versus gallbladder aspiration for acute cholecystitis: a prospective randomized controlled trial. AJR Am J Roentgenol 183:193, 2004
  33. Abou-Saif A, Al-Kawas FH: Complications of gallstone disease: Mirizzi syndrome, cholecystocholedochal fistula, and gallstone ileus. Am J Gastroenterol 97:249, 2002
  34. Gomez G: Mirizzi syndrome. Curr Treat Options Gastroenterol 5:95, 2002
  35. Bennett GL, Balthazar EJ: Ultrasound and CT evaluation of emergent gallbladder pathology. Radiol Clin North Am 41:1203, 2003
  36. Sood BP, Kalra N, Gupta S, et al: Role of sonography in the diagnosis of gallbladder perforation. J Clin Ultrasound 30:270, 2002
  37. Menakuru SR, Kaman L, Behera A, et al: Current management of gall bladder perforations. ANZ J Surg 74:843, 2004
  38. Thornton JR, Heaton KW, Espiner HJ, et al: Empyema of the gall bladder: reappraisal of a neglected disease. Gut 24:1183, 1983
  39. Gill K, Chapman A, Weston M: The changing face of emphysematous cholecystitis. Br J Radiol 70:986, 1997
  40. Lassandro F, Gagliardi N, Scuderi M, et al: Gallstone ileus analysis of radiologic findings in 27 patients. Eur J Radiol 50:23, 2004
  41. Misra S, Chaturvedi A, Misra NC, et al: Carcinoma of the gallbladder. Lancet Oncol 4:167, 2003
  42. Venu RP, Geenen JE, Toouli J, et al: Endoscopic retrograde cholangiopancreatography. Diagnosis of cholelithiasis in patients with normal gallbladder x-ray and ultrasound studies. JAMA 249:758, 1983
  43. Thorboll J, Vilmann P, Jacobsen B, et al: Endoscopic ultrasonography in detection of cholelithiasis in patients with biliary pain and negative transabdominal ultrasonography. Scand J Gastroenterol 39:267, 2004
  44. Dill JE, Hill S, Callis J, et al: Combined endoscopic ultrasound and stimulated biliary drainage in cholecystitis and microlithiasis—diagnoses and outcomes. Endoscopy 27:424, 1995
  45. Dahan P, Andant C, Levy P, et al: Prospective evaluation of endoscopic ultrasonography and microscopic examination of duodenal bile in the diagnosis of cholecystolithiasis in 45 patients with normal conventional ultrasonography. Gut 38:277, 1996
  46. Jacobson BC, Waxman I, Parmar K, et al: Endoscopic ultrasound-guided gallbladder bile aspiration in idiopathic pancreatitis carries a significant risk of bile peritonitis. Pancreatology 2:26, 2002
  47. Wenckert A, Robertson B: The natural course of gallstone disease: eleven-year review of 781 nonoperated cases. Gastroenterology 50:376, 1966
  48. Broughan TA: Gallstones. Curr Treat Options Gastroenterol 2:154, 1999
  49. Petroni ML, Jazrawi RP, Pazzi P, et al: Ursodeoxycholic acid alone or with chenodeoxycholic acid for dissolution of cholesterol gallstones: a randomized multicentre trial. The British-Italian Gallstone Study group. Aliment Pharmacol Ther 15:123, 2001
  50. Thistle JL, May GR, Bender CE, et al: Dissolution of cholesterol gallbladder stones by methyl tert-butyl ether administered by percutaneous transhepatic catheter. N Engl J Med 320:633, 1989
  51. Paumgartner G, Sauter GH: Extracorporeal shock wave lithotripsy of gallstones: 20th anniversary of the first treatment. Eur J Gastroenterol Hepatol 17:525, 2005
  52. Tsumita R, Sugiura N, Abe A, et al: Long-term evaluation of extracorporeal shock-wave lithotripsy for cholesterol gallstones. J Gastroenterol Hepatol 16:93, 2001
  53. Schoenfield LJ, Berci G, Carnovale RL, et al: The effect of ursodiol on the efficacy and safety of extracorporeal shock-wave lithotripsy of gallstones. The Dornier National Biliary Lithotripsy Study. N Engl J Med 323:1239, 1990
  54. Godrey PJ, Bates T, Harrison M, et al: Gall stones and mortality: a study of all gall stone related deaths in a single health district. Gut 25:1029, 1984
  55. Gracie WA, Ransohoff DF: The natural history of silent gallstones: the innocent gallstone is not a myth. N Engl J Med 307:798, 1982
  56. Guidelines for the Treatment of Gallstones. American College of Physicians. Ann Intern Med 119:620, 1993
  57. Ransohoff DF, Miller GL, Forsythe SB, et al: Outcome of acute cholecystitis in patients with diabetes mellitus. Ann Intern Med 106:829, 1987
  58. Friedman LS, Roberts MS, Brett AS, et al: Management of asymptomatic gallstones in the diabetic patient: a decision analysis. Ann Intern Med 109:913, 1988
  59. Ahmed A, Cheung RC, Keeffe EB: Management of gallstones and their complications. Am Fam Physician 61:1673, 2000
  60. Houdart R, Perniceni T, Darne B, et al: Predicting common bile duct lithiasis: determination and prospective validation of a model predicting low risk. Am J Surg 170:38, 1995
  61. Lichtenbaum RA, McMullen HF, Newman RM: Preoperative abdominal ultrasound may be misleading in risk stratification for presence of common bile duct abnormalities. Surg Endosc 14:254, 2000
  62. Kondo S, Isayama H, Akahane M, et al: Detection of common bile duct stones: comparison between endoscopic ultrasonography, magnetic resonance cholangiography, and helical-computed-tomographic cholangiography. Eur J Radiol 54:271, 2005
  63. Aube C, Delorme B, Yzet T, et al: MR cholangiopancreatography versus endoscopic sonography in suspected common bile duct lithiasis: a prospective, comparative study. AJR Am J Roentgenol 184:55, 2005
  64. Ramesh H: A balanced approach to choledocholithiasis. Surg Endosc 15:1494, 2001
  65. NIH state-of-the-science statement on endoscopic retrograde cholangiopancreatography (ERCP) for diagnosis and therapy. NIH Consens State Sci Statements 19:1, 2002
  66. Palazzo L, O'Toole D: EUS in common bile duct stones. Gastrointest Endosc 56(4 suppl):S49, 2002
  67. Mueller PR, vanSonnenberg E, Simeone JF: Fine-needle transhepatic cholangiography: indications and usefulness. Ann Intern Med 97:567, 1982
  68. Vaira D, D'Anna L, Ainley C, et al: Endoscopic sphincterotomy in 1000 consecutive patients. Lancet 2:431, 1989
  69. Hawes RH, Cotton PB, Vallon AG: Follow-up 6 to 11 years after duodenoscopic sphincterotomy for stones in patients with prior cholecystectomy. Gastroenterology 98:1008, 1990
  70. Hawasli A, Lloyd L, Cacucci B: Management of choledocholithiasis in the era of laparoscopic surgery. Am Surg 66:425, 2000
  71. Ponsky JL, Heniford BT, Gersin K: Choledocholithiasis: evolving intraoperative strategies. Am Surg 66:262, 2000
  72. Csendes A, Diaz JC, Burdiles P, et al: Mirizzi syndrome and cholecystobiliary fistula: a unifying classification. Br J Surg 76:1139, 1989
  73. England RE, Martin DF: Endoscopic management of Mirizzi's syndrome. Gut 40:272, 1997
  74. Curet MJ, Rosendale DE, Congilosi S: Mirizzi syndrome in a Native American population. Am J Surg 168:616, 1994
  75. Tsuyuguchi T, Saisho H, Ishihara T, et al: Long-term follow-up after treatment of Mirizzi syndrome by peroral cholangioscopy. Gastrointest Endosc 52:639, 2000
  76. Redaelli CA, Buchler MW, Schilling MK, et al: High coincidence of Mirizzi syndrome and gallbladder carcinoma. Surgery 121:58, 1997
  77. Foutch PG, Kerr D, Harlan JR, et al: Endoscopic retrograde wire-guided brush cytology for diagnosis of patients with malignant obstruction of the bile duct. Am J Gastroenterol 85:791, 1990
  78. Angulo P, Lindor KD: Primary sclerosing cholangitis. Hepatology 30:325, 1999
  79. Lindor KD: Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis—Ursodeoxycholic Acid Study Group. N Engl J Med 336:691, 1997
  80. Johnson GK, Geenen JE, Venu RP, et al: Endoscopic treatment of biliary duct strictures in sclerosing cholangitis: follow-up assessment of a new therapeutic approach. Gastrointest Endosc 33:9, 1987
  81. Buckles DC, Lindor KD, Larusso NF, et al: In primary sclerosing cholangitis, gallbladder polyps are frequently malignant. Am J Gastroenterol 97:1138, 2002
  82. Fan ST, Choi TK, Wong J: Recurrent pyogenic cholangitis: current management. World J Surg 15:248, 1991
  83. Wilson MK, Stephen MS, Mathur M, et al: Recurrent pyogenic cholangitis or “oriental cholangiohepatitis” in occidentals: case reports of four patients. Aust N Z J Surg 66:649, 1996
  84. Kim MJ, Cha SW, Mitchell DG, et al: MR imaging findings in recurrent pyogenic cholangitis. AJR Am J Roentgenol 173:1545, 1999
  85. Jeyarajah DR: Recurrent pyogenic cholangitis. Curr Treat Options Gastroenterol 7:91, 2004
  86. Liu CL, Fan ST, Lo CM, et al: Choledochal cysts in adults. Arch Surg 137:465, 2002
  87. Cheney M, Rustad DG, Lilly JR: Choledochal cyst. World J Surg 9:244, 1985
  88. Todani T, Watanabe Y, Narusue M, et al: Classification, operative procedures, and review of thirty-seven cases including cancer arising from choledochal cyst. Am J Surg 134:263, 1977
  89. Postema RR, Hazebroek FW: Choledochal cysts in children: a review of 28 years of treatment in a Dutch children's hospital. Eur J Surg 165:1159, 1999
  90. Shemesh E, Czerniak A, Klein E, et al: The role of endoscopic retrograde cholangiopancreatography in the diagnosis and treatment of adult choledochal cyst. Surg Gynecol Obstet 167:423, 1988
  91. Terblanche J, Worthley CS, Spence RA, et al: High or low hepaticojejunostomy for bile duct strictures? Surgery 108:828, 1990
  92. Menees S, Elta GH: Sphincter of Oddi dysfunction. Curr Treat Options Gastroenterol 8:109, 2005
  93. Black NA, Thompson E, Sanderson CF: Symptoms and health status before and six weeks after open cholecystectomy: a European cohort study. ECHSS Group. European Collaborative Health Services Study Group. Gut 35:1301, 1994
  94. Luman W, Adams WH, Nixon SN, et al: Incidence of persistent symptoms after laparoscopic cholecystectomy: a prospective study. Gut 39:863, 1996
  95. Toouli J, Roberts-Thomson IC, Dent J, et al: Manometric disorders in patients with suspected sphincter of Oddi dysfunction. Gastroenterology 88(5 pt 1):1243, 1985
  96. Pineau BC, Knapple WL, Spicer KM, et al: Cholecystokinin-stimulated mebrofenin (99mTc-Choletec) hepatobiliary scintigraphy in asymptomatic postcholecystectomy individuals: assessment of specificity, interobserver reliability, and reproducibility. Am J Gastroenterol 96:3106, 2001
  97. Geenen JE, Hogan WJ, Dodds WJ, et al: The efficacy of endoscopic sphincterotomy after cholecystectomy in patients with sphincter-of-Oddi dysfunction. N Engl J Med 320:82, 1989
  98. Wehrmann T, Schmitt TH, Arndt A, et al: Endoscopic injection of botulinum toxin in patients with recurrent acute pancreatitis due to pancreatic sphincter of Oddi dysfunction. Aliment Pharmacol Ther 14:1469, 2000
  99. Moody FG, Becker JM, Potts JR: Transduodenal sphincteroplasty and transampullary septectomy for postcholecystectomy pain. Ann Surg 197:627, 1983

Editors: Dale, David C.; Federman, Daniel D.